Evidence Hub

Impact of metformin therapy on serum visfatin levels in polycystic ovary syndrome: a systematic review and randomized permuted meta-analysis

E. Reddy, Hemanth Raj Thangappazham, Nabnita Patnaik, Pragathi Duggina, Kuladeep L Kumar, Saurabh Varshney, A. Grover, Pratima Gupta et al.

Cellular and Molecular Biology, 2025

1 citation

Abstract

Visfatin, an, is associated with reproductive and metabolic disorders like polycystic ovary syndrome (PCOS). Although visfatin levels are known to be elevated in PCOS, the effect of metformin treatment on these levels remains unclear. This meta-analysis aimed to assess changes in circulating visfatin levels before and after metformin intervention in PCOS patients. Relevant studies were identified through comprehensive searches, and a random-effects meta-analysis was conducted to calculate standardized mean differences (SMDs) with 95% confidence intervals (CIs). Sensitivity analysis and randomized permuted meta-analyses (with 1,000, 10,000, and 100,000 iterations) were performed to validate the findings. The analysis included four studies and showed a significant reduction in visfatin levels following metformin treatment (SMD: -0.45, 95% CI: -0.76 to -0.14, p = 0.0043). These results highlight metformin's impact on visfatin levels in PCOS, though larger trials are needed to further explore visfatin's role as a therapeutic target in PCOS.

How strong is the evidence?

Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free